Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Degenerative joint disease.

R D Altman, M C Hochberg

    Clinics in Rheumatic Diseases
    |December 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Future clinical trials for osteoarthritis (OA) should standardize patient selection, outcome measures like pain via visual analogue scale, and avoid concomitant analgesics for clearer results.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Corrigendum to "Multi-centre modified Delphi exercise to identify candidate items for classifying early-stage symptomatic knee osteoarthritis" [Osteoarthritis Cartilage (2025) 155-165].

    Osteoarthritis and cartilage·2025
    Same author

    Multi-centre modified Delphi exercise to identify candidate items for classifying early-stage symptomatic knee osteoarthritis.

    Osteoarthritis and cartilage·2024
    Same author

    Evaluation of S201086/GLPG1972, an ADAMTS-5 inhibitor, for the treatment of knee osteoarthritis in ROCCELLA: a phase 2 randomized clinical trial.

    Osteoarthritis and cartilage·2023
    Same author

    Reflections from the 2021 OARSI clinical trial symposium: Considerations for understanding biomarker assessments in osteoarthritis drug development - Should future studies focus on disease activity, rather than status?

    Osteoarthritis and cartilage open·2022
    Same author

    A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis.

    Osteoarthritis and cartilage·2021
    Same author

    Evaluating the structural effects of intra-articular sprifermin on cartilage and non-cartilaginous tissue alterations, based on sqMRI assessment over 2 years.

    Osteoarthritis and cartilage·2020
    Same journal

    Metabolic and endocrine aspects of rheumatic disease.

    Clinics in rheumatic diseases·1986
    Same journal

    Muscle 'contractures' and the 'stiff-man' syndrome.

    Clinics in rheumatic diseases·1986
    Same journal

    Hypophosphatasia.

    Clinics in rheumatic diseases·1986
    Same journal

    Alkaptonuria.

    Clinics in rheumatic diseases·1986
    Same journal

    Diabetes mellitus and rheumatic disease.

    Clinics in rheumatic diseases·1986
    Same journal

    Musculoskeletal manifestations of primary hyperparathyroidism.

    Clinics in rheumatic diseases·1986
    See all related articles

    Area of Science:

    • Rheumatology
    • Clinical Trial Design
    • Osteoarthritis Research

    Background:

    • Osteoarthritis (OA) clinical trials present unique challenges in disease classification, patient selection, and outcome measurement.
    • Standardization is needed to improve the reliability and interpretability of OA clinical trial data.

    Purpose of the Study:

    • To propose specific recommendations for optimizing the design of future OA clinical trials.
    • To address key features requiring special attention, including disease classification, patient criteria, and outcome parameters.

    Main Methods:

    • Development of a disease classification schema (detailed in Table 1).
    • Review and recommendation of patient selection and admission criteria for OA studies.
    • Identification and proposal of primary clinical outcome variables for OA trials.

    Related Experiment Videos

    Main Results:

    • Recommends limiting future trials to patients with idiopathic OA affecting specified joints.
    • Suggests using visual analogue scale for pain and global assessments as primary outcome variables.
    • Advocates for the exclusion of concomitant analgesic agents in anti-inflammatory drug trials.

    Conclusions:

    • Standardized approaches to patient stratification and outcome measurement are crucial for robust OA clinical trials.
    • Excluding confounding variables like concomitant analgesics will enhance the validity of anti-inflammatory drug efficacy data.
    • Incorporating validated health status measures in long-term studies will provide comprehensive functional outcome assessments.